Top Suppliers:I want be here


141206-42-0

141206-42-0 structure
141206-42-0 structure
  • Name: Lucerastat
  • Chemical Name: (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
  • CAS Number: 141206-42-0
  • Molecular Formula: C10H21NO4
  • Molecular Weight: 219.27800
  • Catalog: Research Areas Metabolic Disease
  • Create Date: 2016-03-05 00:47:05
  • Modify Date: 2024-01-05 14:35:22
  • Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].

Name (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
Synonyms NB-DGJ
UNII-GVS3YDM418
Lucerastat
N-Butyl-DGJ
N-Bu-DGJ
Description Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Related Catalog
In Vitro Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%). Cell Viability Assay[2]. Cell Line: Fabry patient-derived fibroblasts with the genotypes R301G (residual -GalA activity; 20%) R220X (<3%) and W162X (<1%). Concentration: Incubation Time: 9 days. Result: Dose-dependently inhibited GCS, reducing glucosylceramide and increasing sphingomyelin.
In Vivo Lucerastat (1200 mg/kg/day food admix), a GCS inhibitor, reduces Gb3 in the absence of residual -GalA activity[2]. Animal Model: Fabry mice (Gla-/0 and Gla-/-, n = 5 or 6 for each gender)[2]. Dosage: 1200 mg/kg/day food admix. Administration: Food admix for 20 weeks. Result: Reduced lipid storage in two major organs affected by FD: mean Gb3 in the kidneys (-33%, p<0.01). and α-galactose- terminated glycosphingolipids in the dorsal root ganglia (-48%, p<0.05). In the liver of the Fabry mice, mean glucosylceramide (GlcCer (24:0)) was reduced (-59%, p<0.001) in addition to Gb3 (24:1) (-37%, p<0.05) demonstrating substrate reduction through GCS inhibition.
References

[1]. Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.

[2]. R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.

Molecular Formula C10H21NO4
Molecular Weight 219.27800
Exact Mass 219.14700
PSA 84.16000
Hazard Codes Xn
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.